As per the file enclosed
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.1 pts more than Nifty Microcap 250 and 5.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Venus Remedies reported strong FY2026 results with standalone revenue of Rs 768.73 Cr (up 19.3% from Rs 644.47 Cr in FY2025) and consolidated revenue of Rs 769.60 Cr. Net profit after tax grew significantly to Rs 99.31 Cr standalone and Rs 102.78 Cr consolidated, compared to Rs 52.55 Cr and Rs 45.31 Cr respectively in the previous year. EPS improved to Rs 74.29 (standalone) and Rs 76.89 (consolidated) from Rs 39.32 and Rs 33.89. The Board recommended a final dividend of Rs 10 per share (100%) payable after shareholder approval at the 37th AGM on 20th August 2026 (record date: 7th August 2026). Key board changes include reappointment of Mr. Saransh Chaudhary as Managing Director and appointment of Dr. Savita Gupta as Additional Director (related party). The company adopted new MOA and AOA aligned with Companies Act 2013. Auditors issued an unmodified (clean) opinion on both standalone and consolidated financial statements.
Strong financial performance with near-doubling of PAT and robust revenue growth signals healthy operational performance. The clean audit opinion and shareholder-friendly dividend policy are positive indicators for investors.